Merck & Co Inc

MRK

Equity

ISIN null / Valor 10683053

New York Stock Exchange, Inc (2025-11-21)

USD 97.76+2.94%

Merck & Co Inc
UMushroom community rating:

4.00 5 votes No rating yet

NegativeNeutralPositive

About company

Merck & Co Inc, known outside the United States and Canada as Merck KGaA, Darmstadt, Germany, is a global science and technology company with a focus on healthcare, life sciences, and electronics. Founded in 1851, the company has established itself as a pioneer in the science and technology sector, aiming to leverage its expertise to address some of the world's most pressing challenges, including disease, poverty, hunger, and climate change. Merck & Co Inc is committed to driving innovation and growth through its "Mobilize for Growth" strategy, which seeks to unlock the company's full potential and achieve a target of approximately €25 billion in sales by 2025. A significant portion of this growth is expected to come from its three main business sectors: Process Solutions and Life Science Services within the Life Science sector, new Healthcare products, and Semiconductor Solutions within the Electronics sector. The company emphasizes the importance of quality, sustainability, and corporate responsibility in its operations, aiming to create value not only for its customers and patients but also for society at large.

Summarized from source with an LLMView SourceSector: Healthcare

Total Worldwide Sales

Merck & Co Inc achieved total worldwide sales of $15.8 billion in Q2 2025, marking a 2% decrease from Q2 2024. This decline was consistent both nominally and when excluding the impact of foreign exchange.

KEYTRUDA and Animal Health Growth

KEYTRUDA sales rose by 9% to $8.0 billion, driven by strong demand in metastatic and earlier-stage cancer indications. The Animal Health division saw an 11% increase in sales, reaching $1.6 billion, supported by higher demand for livestock products and the integration of the Elanco aqua business.

GARDASIL Sales Decline

Sales of GARDASIL/GARDASIL 9 declined sharply by 55% to $1.1 billion, primarily due to reduced demand in China and lower immunization program uptake in Japan. U.S. sales saw a modest increase of 2% during the quarter.

Earnings and Strategic Initiatives

Merck reported a GAAP EPS of $1.76 and a non-GAAP EPS of $2.13 for Q2 2025, both including a charge related to the Hengrui Pharma license agreement. The company announced the acquisition of Verona Pharma, expected to close in Q4 2025, and initiated a multiyear optimization plan aiming for $3.0 billion in annual cost savings by the end of 2027.

Future Outlook

For the full year 2025, Merck narrowed its expected worldwide sales to between $64.3 billion and $65.3 billion and its non-GAAP EPS range to between $8.87 and $8.97. These projections exclude the anticipated impact of the Verona Pharma acquisition.

Summarized from source with an LLMView Source

Key figures

-2.10%1Y

-7.43%3Y

27.2%5Y

Performance

29.9%1Y

23.6%3Y

22.9%5Y

Volatility